Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes

BACKGROUND: Both Alzheimer’s disease (AD) and type 2 diabetes (T2D) share common pathological features including inflammation, insulin signaling alterations, or vascular damage. AD has no successful treatment, and the close relationship between both diseases supports the study of antidiabetic drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Hierro-Bujalance, Carmen, Infante-Garcia, Carmen, del Marco, Angel, Herrera, Marta, Carranza-Naval, Maria Jose, Suarez, Javier, Alves-Martinez, Pilar, Lubian-Lopez, Simon, Garcia-Alloza, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140573/
https://www.ncbi.nlm.nih.gov/pubmed/32264944
http://dx.doi.org/10.1186/s13195-020-00607-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140573/
https://www.ncbi.nlm.nih.gov/pubmed/32264944
http://dx.doi.org/10.1186/s13195-020-00607-4

Ejemplares similares